Announced details
74% reduction in work time for release decisions
78% reduction in work time for product quality reviews
As of the end of March 2026, intra-mart had been implemented by more than 13,000 companies. The number of intra-mart implementations and locations at Taiho Pharmaceutical is Not disclosed.
Taiho Pharmaceutical Co., Ltd. is a user of intra-mart. 株式会社日本テクノ開発 is a partner of NTT DATA INTRAMART CORPORATION.
Taiho Pharmaceutical Co., Ltd.: Headquartered in Chiyoda-ku, Tokyo, and led by President Kobayashi Masayuki (小林将之). The company develops consumer healthcare products and prescription pharmaceuticals, with particular strength in the anticancer drug field. 株式会社日本テクノ開発: A partner of NTT DATA INTRAMART CORPORATION that provided comprehensive support for the implementation and development of this system. Other attributes are Not disclosed.
CPU-based pricing model. Specific pricing is Not disclosed.
The impact of this implementation on revenue and profit is Not disclosed.
The company does not address Contract Value.
| Item | Details |
|---|---|
| Names of Products / Services Covered | intra-mart |
| Counterparty | Taiho Pharmaceutical Co., Ltd., 株式会社日本テクノ開発 |
| Counterparty overview | Taiho Pharmaceutical Co., Ltd.: Headquartered in Chiyoda-ku, Tokyo, and led by President Kobayashi Masayuki (小林将之). The company develops consumer healthcare products and prescription pharmaceuticals, with particular strength in the anticancer drug field. 株式会社日本テクノ開発: A partner of NTT DATA INTRAMART CORPORATION that provided comprehensive support for the implementation and development of this system. Other attributes are Not disclosed. |
| Relationship with the Company | Taiho Pharmaceutical Co., Ltd. is a user of intra-mart. 株式会社日本テクノ開発 is a partner of NTT DATA INTRAMART CORPORATION. |
| Offering price | CPU-based pricing model. Specific pricing is Not disclosed. |
| Applicable area | Quality management in the pharmaceutical industry, GMP release decisions, Product quality reviews, Manufacturing and quality management operations |
| Quantitative Effects | 74% reduction in work time for release decisions, 78% reduction in work time for product quality reviews |
| Usage history | As of the end of March 2026, intra-mart had been implemented by more than 13,000 companies. The number of intra-mart implementations and locations at Taiho Pharmaceutical is Not disclosed. |
| Impact on Business Performance | The impact of this implementation on revenue and profit is Not disclosed. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To streamline data collection and verification from multiple systems and paper documents, analysis that had become dependent on individual employees, and cross-checking required to ensure data integrity, thereby optimizing the overall business process.